Tamtam Try Tamtam free
Bio-Techne logo

Bio-Techne account plan

Protein and diagnostics solutions

At a glance

Bio-Techne makes life science reagents, instruments and diagnostics; FY2026 net sales $1,215.0 million, about 3,000 staff, being acquired by Merck KGaA.

Bio-Techne, headquartered in Minneapolis and listed on NASDAQ (TECH), develops, manufactures and sells life science reagents, instruments and services for the research, diagnostics and bioprocessing markets. Its customers are academic and industry researchers (chiefly pharma, biotech and CROs), diagnostic developers and cell- and gene-therapy developers. In the fiscal year ended June 30, 2026 it reported net sales of $1,215.0 million, flat on FY2025, and GAAP net earnings of $181.9 million; it had about 3,000 employees, about 2,200 of them in the U.S. Revenue is consumables-heavy ($985.1 million in FY2026), and most products are manufactured in-house in North America, the U.K., Canada, Switzerland and China. On June 25, 2026 it agreed to be acquired by Merck KGaA, Darmstadt, Germany, for $73.00 per share in cash; shareholders approved the deal on September 23, 2026 and closing is expected by late 2026 or early 2027.

Business units

Strategic priorities

Closing the Merck KGaA merger
Merck KGaA agreed to buy Bio-Techne at $73.00 per share, an enterprise value of about US$11.3 billion; shareholders approved it on September 23, 2026 and closing is expected by late 2026 or early 2027. Merck KGaA targets about EUR 140 million of annual cost synergies, fully realized by year 3 after closing.
Four growth verticals
Cell therapy, proteomic analysis, spatial biology and precision diagnostics were 47% of total revenue in Q2 FY2026, up from 32% in fiscal 2020, and address a $27 billion market growing at a mid-teens rate, all pulling through the core reagents.
Brand simplification
In April 2026 the company moved from 10 brands to 3 (R&D Systems, Bio-Techne Spatial Biology, Bio-Techne Diagnostics), and a Q4 FY2026 restructuring for a streamlined brand architecture and realigned functions continues into fiscal 2027.
Margin expansion
The CEO expects gross margin to stay north of 70% and, under normalized growth, margins to improve by at least a hundred basis points annually, helped by productivity, AI and the exit from lower-margin businesses.
AI-designed proteins and data
Bio-Techne uses AI models trained on five decades of proprietary data to design novel, patentable proteins, deploys AI across the organisation for productivity and customer engagement, and labels data so customers can use it with large language models.
Cell therapy and GMP capacity
GMP reagents grew nearly 50% in Q3 FY2026 excluding two Fast Track customers; the cell therapy base counts 700+ customers and 85 programmes in clinical trials, and the CEO wants at least 20% trailing-12-month growth in cell therapy.

Latest results

In Q1 FY2027 (quarter to September 30, 2026) net sales were $299.7 million, up 5%, with organic growth of 7% and a 2% headwind from the divested Exosome Diagnostics business. Protein Sciences grew 9% to $219.7 million, while Diagnostics and Spatial Biology grew 1% to $80.2 million and its operating margin fell to 7.4% from 11.2%. GAAP net earnings fell to $28.3 million (diluted EPS $0.18 vs $0.24) as acquisition-related expenses rose to $17.9 million; adjusted EPS was $0.44 vs $0.42 and adjusted gross margin 69.3% vs 70.2%. Operating cash flow was $73.1 million and cash $350.0 million. No numeric guidance is given in the filings; on the Q3 FY2026 call the CFO said the company would be disappointed without at least mid-single-digit growth in fiscal 2027.

Investments and deals

Wilson Wolf buyout
Bio-Techne owns 19.9% of Wilson Wolf (G-Rex cell culture devices) and must buy the remaining 80.1% by December 31, 2027 for about $1 billion plus potential contingent consideration, forecast between fiscal 2027 and fiscal 2028.
Capacity capex
Capital additions were $28.9 million in FY2026; about $28 million more is expected in fiscal 2027 for capacity to meet expected sales growth.
Exosome Diagnostics divestiture
Exosome Diagnostics was sold for MDxHealth shares received in September 2025, after a cumulative impairment of $83.1 million; a $5.9 million loss on the MDxHealth investment was booked in FY2026.
Restructuring programmes
The FY2025 margin-recovery and manufacturing-footprint programme was completed by the end of fiscal 2026; restructuring and related costs totalled $21.1 million in FY2026, and a new Q4 programme runs through fiscal 2027.
New products and earlier deals
Over 1,900 new products were launched in FY2026, including the Leo high-throughput western blot and CE-IVD marking for Ella; earlier moves include Lunaphore, acquired for $169.7 million, and a $15.0 million investment in Spear Bio in fiscal 2025.

Challenges and risks

Merger disruption
The 10-K flags substantial transaction costs, difficulty retaining personnel and senior management, and strain on relationships with customers, suppliers and distributors while the deal is pending; buybacks are prohibited without Merck KGaA's consent.
Mix and pricing pressure
Adjusted gross margin slipped to 69.6% in FY2026 from 70.4%, and Protein Sciences sales were impacted by unfavorable product mix and pricing pressures.
Uneven end markets
Emerging biotech fell high single digits in Q3 FY2026 as funding moved toward late-stage programmes, and the CEO called academia still a frail market; U.S. sales fell to $635.4 million in FY2026 from $683.2 million.
Customer concentration in cell therapy
Two cell therapy customers with FDA Fast Track designation cut GMP reagent sales by 50% in Q2 FY2026 and created a 400 basis point headwind in Q3 FY2026.
Diagnostics order timing
Bulk diagnostic lots ship on customer schedules, so revenue can swing from quarter to quarter, and the segment's operating margin fell to 7.4% in Q1 FY2027.

What leadership says

“As part of Merck KGaA, Darmstadt, Germany, we will have greater scale and expanded capabilities to accelerate innovation and deepen our impact.”

Kim Kelderman, President and CEO · Joint press release on the Merck KGaA acquisition, June 25, 2026

“We should be able under normalized growth conditions to improve our margins by at least a hundred basis points annually.”

Kim Kelderman, President and CEO · TD Cowen Insights podcast, recorded March 3, 2026

“we'd be disappointed if we didn't do at least mid-single-digit growth”

James Hippel, CFO · Q3 fiscal 2026 earnings call, May 6, 2026, on fiscal 2027

“It's still a frail market. It's certainly not going to be a V-shaped recovery”

Kim Kelderman, President and CEO · Q3 fiscal 2026 earnings call, May 6, 2026, on academia

Where a supplier can help

Integration support ahead of the Merck KGaA close
Tied to the pending merger and its EUR 140 million cost-synergy target: systems, data migration and change-management providers can help align processes, while vendor decisions may move toward the acquirer's structures.
Brand consolidation execution
Tied to the move from 10 brands to 3 and the restructuring running through fiscal 2027: digital catalogue, web, product-data and marketing-operations suppliers can help make products easier to find on digital and AI-driven platforms.
Manufacturing capacity and GMP quality
Tied to the fiscal 2027 capacity capex and cell therapy growth goals: equipment, automation, quality and validation suppliers fit the GMP reagent build-out.
Productivity and AI tooling
Tied to the margin-expansion priority and AI use across the organisation: automation, analytics and AI platform providers can support productivity gains.
Talent retention during the transaction
Tied to the merger challenge of retaining personnel: HR, engagement and recruiting providers can help keep critical scientific and commercial staff.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Bio-Techne?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Bio-Techne

What does Bio-Techne do?

Bio-Techne makes life science reagents, instruments and services for research, diagnostics and bioprocessing, through two segments: Protein Sciences and Diagnostics and Spatial Biology. Its brands include R&D Systems, Bio-Techne Spatial Biology and Bio-Techne Diagnostics.

What is Bio-Techne's revenue?

Net sales were $1,215.0 million in the fiscal year ended June 30, 2026, flat on FY2025's $1,219.6 million. In Q1 FY2027 net sales were $299.7 million, up 5%.

How many employees does Bio-Techne have?

About 3,000 at June 30, 2026, with about 2,200 in the U.S. and about 800 outside.

Who is acquiring Bio-Techne?

Merck KGaA, Darmstadt, Germany, agreed on June 25, 2026 to acquire Bio-Techne for $73.00 per share in cash. Shareholders approved the deal on September 23, 2026, and closing is expected by late 2026 or early 2027.

Who leads Bio-Techne?

Kim Kelderman is President and CEO, James Hippel is CFO, William Geist leads Protein Sciences and Steve Crouse leads Diagnostics and Spatial Biology.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)